19 May 2013
Keywords: sb, tagamet, otc, approval, usa, smithkline, beecham
Article | 26 June 1995
SmithKline Beecham has received clearance from the US Food and Drug
Administration to market its histamine H2 receptor antagonist,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 June 1995
17 May 2013
© 2013 thepharmaletter.com